Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Alzheimer'S Research & Therapy|January 31, 2014
Active immunotherapy options for Alzheimer's diseaseBengt Winblad, Ana Graf, Marie-Emmanuelle Riviere, et al.
Alzheimer'S Research & Therapy|April 29, 2015
Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's diseaseMartin R Farlow, Niels Andreasen, Marie-Emmanuelle Riviere, et al.
Alzheimer'S Research & Therapy|March 6, 2023
Rationale for the selection of dual primary endpoints in prevention studies of cognitively unimpaired individuals at genetic risk for developing symptoms of Alzheimer's diseaseAngelika Caputo, Amy Racine, Ines Paule, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 26, 2017
Active Aβ immunotherapy CAD106 in Alzheimer's disease: A phase 2b studyRik Vandenberghe, Marie-Emmanuelle Riviere, Angelika Caputo, et al.
Alzheimer'S Research & Therapy|May 29, 2020
The Alzheimer's Prevention Initiative Composite Cognitive Test: a practical measure for tracking cognitive decline in preclinical Alzheimer's diseaseJessica B Langbaum, Noel N Ellison, Angelika Caputo, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2023
Effects of the active amyloid beta immunotherapy CAD106 on PET measurements of amyloid plaque deposition in cognitively unimpaired APOE ε4 homozygotesMarie-Emmanuelle Riviere, Jessica B Langbaum, R Scott Turner, et al.
Alzheimer'S & Dementia (New York, N. Y.)|January 11, 2020
Alzheimer's Prevention Initiative Generation Program: Development of an <i>APOE</i> genetic counseling and disclosure process in the context of clinical trialsCarolyn M Langlois, Angela Bradbury, Elisabeth M Wood, et al.
Alzheimer'S & Dementia (New York, N. Y.)|June 19, 2019
The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's diseaseCristina Lopez Lopez, Pierre N Tariot, Angelika Caputo, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 25, 2024
Reversibility of cognitive worsening observed with BACE inhibitor umibecestat in the Alzheimer's Prevention Initiative (API) Generation StudiesPierre N Tariot, Marie-Emmanuelle Riviere, Stephen Salloway, et al.
The Lancet. Healthy Longevity|November 30, 2025
Impact of learning APOE genotype on cognitively unimpaired adults: a pre-screening cohort study of the Alzheimer's Prevention Initiative Generation Study 1Jessica B Langbaum, Angela R Bradbury, Brian L Egleston, et al.
Pageof 1